Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department
Free-to-read version at publisher website
Description
BACKGROUND: Testing for high-sensitivity cardiac troponin (hs-cTn) may assist triage and clinical decision-making in patients presenting to the emergency department with symptoms of acute coronary syndrome; however, this could result in the misclassification of risk because of analytical variation or laboratory error. We sought to evaluate a new laboratorybased risk-stratification tool that incorporates tests for hs-cTn, glucose level and estimated glomerular filtration rate to identify patients at risk of myocardial infarction or death when presenting to the emergency department.
METHODS: We constructed the clinical chemistry score (CCS) (range 0-5 points) and validated it as a predictor of 30-day myocardial infarction (MI) or death using data from 4 cohort studies involving patients who presented to the emergency department with symptoms suggestive of acute coronary syndrome. We calculated diagnostic parameters for the CCS score separately using high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT).
RESULTS: For the combined cohorts (n = 4245), 17.1% of participants had an MI or died within 30 days. A CCS score of 0 points best identified low-risk participants: The hs-cTnI CCS had a sensitivity of 100% (95% confidence interval [CI] 99.5%-100%), with 8.9% (95% CI 8.1%-9.8%) of the population classified as being at low risk of MI or death within 30 days; the hs-cTnT CCS had a sensitivity of 99.9% (95% CI 99.2%-100%), with 10.5% (95% CI 9.6%-11.4%) of the population classified as being at low risk. The CCS had better sensitivity than hscTn alone (hs-cTnI 5 ng/L: 96.6%, 95% CI 95.0%-97.8%; hs-cTnT 6 ng/L: 98.2%, 95% CI 97.0%-99.0%). A CCS score of 5 points best identified patients at high risk (hs-cTnI CCS: Specificity 96.6%, 95% CI 96.0%-97.2%; 11.2% [95% CI 10.3%-12.2%] of the population classified as being at high risk; hs-cTnT CCS: Specificity 94.0%, 95% CI 93.1%-94.7%; 13.1% [95% CI 12.1%-14.1%] of the population classified as being at high risk) compared with using the overall 99th percentiles for the hs-cTn assays (specificity of hs-cTnI 93.2%, 95% CI 92.3-94.0; specificity of hs-cTnT 73.8%, 95% CI 72.3-75.2).
INTERPRETATION: The CCS score at the chosen cut-offs was more sensitive and specific than hs-cTn alone for risk stratification of patients presenting to the emergency department with suspected acute coronary syndrome.
Impact and interest:
Citation counts are sourced monthly from Scopus and Web of Science® citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.
| ID Code: | 197679 | ||||
|---|---|---|---|---|---|
| Item Type: | Contribution to Journal (Journal Article) | ||||
| Refereed: | Yes | ||||
| ORCID iD: |
|
||||
| Measurements or Duration: | 11 pages | ||||
| DOI: | 10.1503/cmaj.180144 | ||||
| ISSN: | 0820-3946 | ||||
| Pure ID: | 46536931 | ||||
| Divisions: | Past > QUT Faculties & Divisions > Faculty of Health | ||||
| Funding Information: | This study was approved by the Hamilton Integrated Research Ethics Board, the Royal Brisbane and Women’s Hospital Human Research Ethics Committee, the New Zealand Health and Disability Ethics Committee, and the local ethics board of Hamburg (Ethics committee of the Ärztekammer Hamburg, Germany). We followed the Standards for the Reporting of Diagnostic Accuracy Studies guideline. Competing interests: Peter Kavsak has received research grants from the Canadian Institutes of Health Research (CIHR), Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Randox Laboratories, Roche Diagnostics and Siemens Healthcare Diagnostics. He has received consultant or advisor fees, or honoraria from Abbott Laboratories, Abbott Point of Care, Abbott Diagnostics Division of Canada, Beckman Coulter, Randox Laboratories, Roche Diagnostics, Siemens Healthcare Diagnostics and Ortho Clinical Diagnostics. In addition, he has a pending patent application filed by McMaster University on a laboratory score for risk stratification in patients with possible cardiac injury. Johannes Neumann has received research grants from the German Heart Foundation/German Foundation of Heart Research and from Else Kröner Fresenius Stiftung. Louise Cullen has received grants from Abbott Diagnostics, Roche and Alere, and personal fees for education and consulting from Abbott Diagnostics, Siemens, Beckman Coulter and Alere. Martin Than has received grants and personal fees in the form of speaker fees or funding for education from Abbott, Alere, Beckman Coulter and Roche. Colleen Shortt is employed by Abbott Diagnostics. Jaimi Greenslade has received research grants that were provided to his institution from Roche and Abbott, as well as a research grant from Emergency Medicine Foundation to support data collection for this study. John Pickering has received nonfinancial support from Abbott Diagnostics and Roche Diagnostics outside the submitted work. Dirk Westermann has received speaker fees from Bayer, Boehringer Ingelheim, Berlin-Chemie, AstraZeneca, BIOTRONIK and Novartis, outside the submitted work. William Parsonage has received research grants from Abbott Laboratories and Roche during the conduct of the study, and fees for being an advisory board member and nonfinancial support from Abbott Laboratories, outside the submitted work. P.J. Devereaux reports grants from Abbott Diagnostics, Boehringer Ingelheim, Covidien, Octopharma, Philips Healthcare, Roche Diagnostics and Stryker, outside the submitted work. Richard Troughton has received research grants from the Health Research Council of New Zealand, Roche Diagnostics and Merck, as well as consulting fees from Merck. Stefan Blankenberg has received honoraria from Abbott Diagnostics, Siemens, Thermo Fisher Scientific and Roche Diagnostics, outside the submitted work. Andrew Worster has received a research grant from CIHR. In addition, he has a pending patent application filed by McMaster University on a laboratory score for risk stratification for patients with possible cardiac injury. No other competing interests were declared. Funding: This study was supported by a Canadian Institutes of Health Research grant, with reagent support from Abbott Laboratories and Roche Diagnostics. | ||||
| Copyright Owner: | 2018 Joule Inc. or its licensors | ||||
| Copyright Statement: | This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au | ||||
| Deposited On: | 17 Mar 2020 05:56 | ||||
| Last Modified: | 10 May 2024 16:50 |
Export: EndNote | Dublin Core | BibTeX
Repository Staff Only: item control page
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)